Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism

被引：61

作者：

Tang, Jun ^{[1
,2
]}

Ye, Lifang ^{[1
,2
]}

Yan, Qiqi ^{[1
,2
]}

Zhang, Xin ^{[1
,2
]}

Wang, Lihong ^{[1
,2
]}

机构：

[1] Zhejiang Chinese Med Univ, Clin Med Coll 2, Hangzhou, Peoples R China

[2] Hangzhou Med Coll, Zhejiang Prov Peoples Hosp, Dept Cardiovasc Med, Peoples Hosp, Hangzhou, Peoples R China

来源：

FRONTIERS IN PHARMACOLOGY | 2022年 / 13卷

基金：

中国国家自然科学基金;

关键词：

sodium-glucose cotransporter 2 inhibitor; heart failure; diuretic effect; natriuresis; glycosuria; HEART-FAILURE; DIABETES-MELLITUS; SGLT2; INHIBITORS; BLOOD-PRESSURE; DAPAGLIFLOZIN TREATMENT; ARTERIAL STIFFNESS; KIDNEY-DISEASE; DOUBLE-BLIND; WEIGHT-LOSS; FAT MASS;

D O I：

10.3389/fphar.2022.800490

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Sodium-glucose cotransporter 2 (SGLT2) inhibitors exert hypoglycemic and diuretic effects by inhibiting the absorption of sodium and glucose from the proximal tubule. Currently available data indicate that SGLT2 inhibitors transiently enhance urinary sodium excretion and urinary volume. When combined with loop diuretics, SGLT2 inhibitors exert a synergistic natriuretic effect. The favorable diuretic profile of SGLT2 inhibitors may confer benefits to volume management in patients with heart failure but this natriuretic effect may not be the dominant mechanism for the superior long-term outcomes observed with these agents in patients with heart failure. The first part of this review explores the causes of transient natriuresis and the diuretic mechanisms of SGLT2 inhibitors. The second part provides an overview of the synergistic effects of combining SGLT2 inhibitors with loop diuretics, and the third part summarizes the mechanisms of cardiovascular protection associated with the diuretic effects of SGLT2 inhibitors.

引用

页数：12

共 122 条

[91] Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects [J].

Sano, Motoaki ;

Goto, Shinichi .

CIRCULATION, 2019, 139 (17) :1985-1987

[92] Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction [J].

Santos-Gallego, Carlos G. ;

Vargas-Delgado, Ariana P. ;

Requena-Ibanez, Juan Antonio ;

Garcia-Ropero, Alvaro ;

Mancini, Donna ;

Pinney, Sean ;

Macaluso, Frank ;

Sartori, Samantha ;

Roque, Merce ;

Sabatel-Perez, Fernando ;

Rodriguez-Cordero, Anderly ;

Zafar, M. Urooj ;

Fergus, Icilma ;

Atallah-Lajam, Farah ;

Contreras, Johanna P. ;

Varley, Cathleen ;

Moreno, Pedro R. ;

Abascal, Vivian M. ;

Lala, Anuradha ;

Tamler, Ronald ;

Sanz, Javier ;

Fuster, Valentin ;

Badimon, Juan J. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (03) :243-255

[93] Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics [J].

Santos-Gallego, Carlos G. ;

Antonio Requena-Ibanez, Juan ;

San Antonio, Rodolfo ;

Ishikawa, Kiyotake ;

Watanabe, Shin ;

Picatoste, Belen ;

Flores, Eduardo ;

Garcia-Ropero, Alvaro ;

Sanz, Javier ;

Hajjar, Roger J. ;

Fuster, Valentin ;

Badimon, Juan J. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (15) :1931-1944

[94] Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial [J].

Scholtes, Rosalie A. ;

Muskiet, Marcel H. A. ;

van Baar, Michiel J. B. ;

Hesp, Anne C. ;

Greasley, Peter J. ;

Karlsson, Cecilia ;

Hammarstedt, Ann ;

Arya, Niki ;

van Raalte, Daniel H. ;

Heerspink, Hiddo J. L. .

DIABETES CARE, 2021, 44 (02) :440-447

[95] BLOOD-VOLUME FOLLOWING DIURESIS INDUCED BY FUROSEMIDE [J].

SCHUSTER, CJ ;

WEIL, MH ;

BESSO, J ;

CARPIO, M ;

HENNING, RJ .

AMERICAN JOURNAL OF MEDICINE, 1984, 76 (04) :585-592

[96] Sodium and Fluid Excretion With Torsemide in Healthy Subjects is Limited by the Short Duration of Diuretic Action [J].

Shah, Salim ;

Pitt, Bertram ;

Brater, D. Craig ;

Feig, Peter U. ;

Shen, Wen ;

Khwaja, Fatima S. ;

Wilcox, Christopher S. .

JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2017, 6 (10)

[97] Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial [J].

Singh, Jagdeep S. S. ;

Mordi, Ify R. ;

Vickneson, Keeran ;

Fathi, Amir ;

Donnan, Peter T. ;

Mohan, Mohapradeep ;

Choy, Anna Maria J. ;

Gandy, Stephen ;

George, Jacob ;

Khan, Faisel ;

Pearson, Ewan R. ;

Houston, J. Graeme ;

Struthers, Allan D. ;

Lang, Chim C. .

DIABETES CARE, 2020, 43 (06) :1356-1359

[98] Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study [J].

Solini, Anna ;

Giannini, Livia ;

Seghieri, Marta ;

Vitolo, Edoardo ;

Taddei, Stefano ;

Ghiadoni, Lorenzo ;

Bruno, Rosa Maria .

CARDIOVASCULAR DIABETOLOGY, 2017, 16

[99] Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes [J].

Sugiyama, Seigo ;

Jinnouchi, Hideaki ;

Kurinami, Noboru ;

Hieshima, Kunio ;

Yoshida, Akira ;

Jinnouchi, Katsunori ;

Nishimura, Hiroyuki ;

Suzuki, Tomoko ;

Miyamoto, Fumio ;

Kajiwara, Keizo ;

Jinnouchi, Tomio .

JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2018, 25 (06) :467-476

[100] Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure [J].

Swedberg, Karl ;

Young, James B. ;

Anand, Inder S. ;

Cheng, Sunfa ;

Desai, Akshay S. ;

Diaz, Rafael ;

Maggioni, Aldo P. ;

McMurray, John J. V. ;

O'Connor, Christopher ;

Pfeffer, Marc A. ;

Solomon, Scott D. ;

Sun, Yan ;

Tendera, Michal ;

van Veldhuisen, Dirk J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (13) :1210-1219

← 4 5 6 7 8 9 10 11 12 13 →